PLRX Pliant Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 11 May 2022 Pliant Therapeutics to Participate in Upcoming Investor Conferences

   SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, will participate in the following May investor conferences.
   

   • 2022 RBC Capital Markets Global Healthcare: Dr. Coulie will participate in a fireside chat on Wednesday, May 18, at 10:00 a.m. ET / 7:00 a.m. PT
   • H.C. Wainwright Global Investment Conference: Dr. Coulie will participate in a fireside chat, the replay of which will be available Monday, May 23, at 7:00 a.m. ET

   Interested parties can access these fireside chats…

   View Full Article
2. 09 May 2022 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

   $100 million Oxford loan facility extends cash runway to mid-2024

   FDA Fast Track designation granted to PLN-74809 in IPF
   

   INTEGRIS-IPF Phase 2a data readout in mid-2022

   EMA Orphan Drug designation granted to PLN-74809 in PSC

   SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported first quarter 2022 financial results.

   "Our achievements so far in 2022 have built on the momentum we generated last year. We've advanced our portfolio, built upon the favorable safety profile of our lead asset and strengthened our financial position…

   View Full Article
3. 05 May 2022 Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

   Up to $100 million of non-dilutive capital from Oxford Finance LLC
   

   Extends expected cash runway to mid-2024

   SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced it has entered into a loan facility agreement with Oxford Finance LLC for up to $100 million of non-dilutive financing. This facility will support the continued clinical development of PLN-74809, an oral, small molecule, dual selective inhibitor of α_vß₆ and α_vß₁ integrins, in the lead indications of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

   "This non-dilutive…

   View Full Article
4. 03 May 2022 Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

   SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ:PLRX) announced today that PLN-74809, its oral, dual-selective α_vß₆/α_vß₁ integrin inhibitor, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of idiopathic pulmonary fibrosis (IPF). PLN-74809, the Company's lead drug candidate, is currently being tested as part of the INTEGRIS-IPF Phase 2a clinical trial (NCT04396756). Pliant anticipates topline data from this randomized, double-blind, placebo-controlled trial in patients with IPF, in mid-2022.
   

   "The Fast Track designation marks an important step in PLN-74809's clinical development in IPF. It underscores the urgent need for new therapeutic…

   View Full Article
5. 02 May 2022 Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

   Five posters include data across biomarker, target engagement, and mechanism studies supporting
   development of PLN-74809, a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF
   

   Pliant selected for featured presentation at the ATS 2022 Respiratory Innovation Summit

   SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present five scientific posters at the upcoming 2022 American Thoracic Society (ATS) International Conference, taking place May 13-18, 2022, in San Francisco, California.

   "Our presence at this year's…

   View Full Article